Category Archives: Global News Feed

SAN DIEGO, April 12, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today the pricing of an underwritten follow-on offering of 5,625,563 shares of its common stock at a price to the public of $22.22 per share. All of the shares to be sold in the offering are to be sold by Crinetics. The gross proceeds to Crinetics from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $125.0 million. The offering is expected to close on or about April 18, 2022, subject to the satisfaction of customary closing conditions.

See the original post here:
Crinetics Pharmaceuticals Announces Pricing of Underwritten Common Stock Offering

Top-line Data Scheduled to Report in Q2 2022

Continue reading here:
Addex Therapeutics Completes Patient Enrollment for Dipraglurant Blepharospasm Phase 2 Clinical Study

Ad hoc announcement pursuant to Art. 53 LR

See original here:
Santhera Appoints Shabir Hasham as Chief Medical Officer and Member of the Executive Management Team

Basel, Switzerland, April 13, 2022

Read the original here:
Basilea reports preclinical data on oncology drug candidates BAL0891, derazantinib and lisavanbulin at AACR Annual Meeting

The trial is single center, prospective study to collect coincident samples of oral fluid and blood to evaluate the time-course of glucose

Follow this link:
GBS Inc. Announces Institutional Review Board Approval to Initiate Clinical Trial at Sutter Health Mills-Peninsula Medical Center

- SELLAS In-licenses Worldwide Rights Outside of Greater China for Clinical-Stage Asset -

Read more:
SELLAS Life Sciences Signs Exclusive License Agreement with GenFleet Therapeutics for Next-Generation, Highly Selective CDK9 Inhibitor